35.44

0.84% -0.30

After Hours: 35.44

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $35.44, with a volume of 583.59K. It is down -0.84% in the last 24 hours and up +10.96% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Previous Close:

$35.74

Open:

$35.86

24h Volume:

583.59K

Relative Volume:

0.52

Market Cap:

$4.14B

Revenue:

$22.57M

Net Income/Loss:

$-212.73M

P/E Ratio:

-19.64

EPS:

-1.8045

Net Cash Flow:

$-142.19M

1W Performance:

+0.00%

1M Performance:

+10.96%

6M Performance:

-7.39%

1Y Performance:

+93.87%

1-Day Range:

$35.01

$36.73

1-Week Range:

$32.96

$36.73

52-Week Range:

$16.79

$42.20

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

100

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	35.44	4.18B	22.57M	-212.73M	-142.19M	-1.8045
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Oct-20-25	Resumed	H.C. Wainwright	Buy
Aug-25-25	Initiated	Wells Fargo	Overweight
Jul-17-25	Initiated	Goldman	Neutral
Jun-17-25	Initiated	Citigroup	Buy
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

May 25, 2026

Technical Reactions to NAMS Trends in Macro Strategies - Stock Traders Daily

May 25, 2026

May 22, 2026

NewAmsterdam Pharma Co NV (HAM:KH6) Cyclically Adjusted Pri - GuruFocus

May 22, 2026

May 14, 2026

Bain Life Sciences trims NewAmsterdam (NAMS) holding to about 3.3% - Stock Titan

May 14, 2026

Trading the Move, Not the Narrative: (NAMS) Edition - Stock Traders Daily

May 14, 2026

NewAmsterdam Pharma Company N.V.Ordinary Shares (NQ: NAMS - FinancialContent

May 14, 2026

Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts - Sahm

May 14, 2026

May 13, 2026